LP
TRDA icon

Longaeva Partners’s Entrada Therapeutics TRDA Stock Holding History

Longaeva Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Sell
195,237
-9,741
-5% -$93.4K 0.03% 276
2026
Q1 		$2.59M Buy
+204,978
New +$2.35M 0.1% 141

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Longaeva Partners's TRDA Position: Q2 2026 in Review

Longaeva Partners reduced its Entrada Therapeutics (TRDA) stake by 4.8% in Q2 2026, selling an estimated $93.4K and leaving 195,237 shares worth $1.44M. The position accounts for 0.03% of the portfolio, ranked #276.

Longaeva Partners first reported a position in TRDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.59M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Longaeva Partners held 195,237 shares of Entrada Therapeutics worth $1.44M as of Q2 2026.
  • Longaeva Partners sold 9,741 Entrada Therapeutics shares in Q2 2026, an estimated $93.4K.
  • Entrada Therapeutics made up 0.03% of Longaeva Partners's portfolio in Q2 2026, its #276 holding.
  • Longaeva Partners first reported a position in Entrada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Longaeva Partners's Entrada Therapeutics position peaked at $2.59M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.